International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety

Pierre‐François Laterre; David R. Nelson; William L. Macias; Edward Abraham; Andreas Sashegyi; Mark D. Williams; Mitchell M. Levy; Marcel Levi; Barbara G. Utterback; Jean Louis Vincent

doi:10.1016/j.jcrc.2006.09.007

Back

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety

Article 2007 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2007

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis

Jean Louis Vincent, James M. O’Brien, Arthur P. Wheeler, Xavier Wittebole, Rekha Garg, Benjamin Trzaskoma, David P. Sundin

Article2003

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*

Derek C. Angus, Walter T. Linde‐Zwirble, Gilles Clermont, Daniel Ball, Bruce R. Basson, E. Wesley Ely, Pierre‐François Laterre, Jean Louis Vincent, Gordon R. Bernard, Ben van Hout

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety

Discussion(0)

Related publications

Drotrecogin alfa (activated): the treatment for severe sepsis?

Drotrecogin alfa (activated) in the treatment of severe sepsis

Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*